COLLEGIUM PHARMACEUTICAL, INC
For the period ended May 12, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 12, 2026 · Filed May 12, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Leadership Updates
Leadership Updates
The Company also announced two leadership updates.
Scott Dreyer will depart from his role as Chief Commercial Officer effective at the end of August 2026 and will remain with the Company through that time to support a smooth transition.
In addition, Thomas Smith, M.D., will depart from his role as Chief Medical Officer following a transition period during which the Company will conduct a search for his successor.
“I want to thank Scott and Tom for their leadership and meaningful contributions to Collegium,” said Vikram Karnani. “Scott has played an important role in building and scaling our commercial organization, and Tom has helped shape our medical and scientific foundation. We are grateful for their commitment and impact.”
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.